A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, ...
Oct 22, 2013
0
0
Despite the success of recent approved therapeutics to treat advanced melanoma, metastatic cancer cells inevitably evolve resistance to drugs. In the journal Cell Reports, a team of researchers based at The Wistar Institute, ...
Sep 19, 2013
0
0
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression ...
Jun 2, 2013
0
0
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.
Jul 16, 2012
0
0
Two new experimental treatments against advanced melanoma have shown promise in keeping the deadly skin cancer at bay, according to research presented in the United States on Monday.
Jun 4, 2012
0
0
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.
Apr 1, 2012
0
0
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit ...
Aug 2, 2011
0
0
An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine along with other Cancer Centers, suggests that an experimental therapy may have promising ...
May 26, 2023
0
4
Patients with metastatic colorectal cancer harboring a subset of non-V600 mutations in the BRAF gene, known as class 3 BRAF mutations, were more likely to respond to anti-EGFR treatment.
Sep 12, 2019
0
4
A 47-year-old American woman with intrahepatic cholangiocarcinoma (ICC) is the first person with her condition to receive a uniquely personalised treatment based on her genetic profile.
Nov 7, 2014
0
0
